Evidence map›Paper›PMID 35056127›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Fabrication and Evaluation of Quercetin Nanoemulsion: A Delivery System with Improved Bioavailability and Therapeutic Efficacy in Diabetes Mellitus.

Manohar Mahadev, Hittanahalli S Nandini, Ramith Ramu, Devegowda V Gowda, Zainab M Almarhoon, Mohammed Al-Ghorbani, Yahia N Mabkhot

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Nano Drug Delivery Strategies for an Oral Bioenhanced Quercetin Formulation.European journal of drug metabolism and pharmacokinetics · 2023
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Manohar MahadevDepartment of Pharmaceutics, JSS College of Pharmacy, JSS AHER, Mysuru 570015, India.
Hittanahalli S NandiniDepartment of Pharmacology, JSS College of Pharmacy, JSS AHER, Mysuru 570015, India.
Ramith RamuDepartment of Biotechnology and Bioinformatics, Faculty of Life Sciences, JSS AHER, Mysuru 570015, India.
Devegowda V GowdaDepartment of Pharmaceutics, JSS College of Pharmacy, JSS AHER, Mysuru 570015, India.
Zainab M AlmarhoonDepartment of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.ORCID 0000-0001-8196-2612
Mohammed Al-GhorbaniDepartment of Chemistry, College of Science and Arts Ulla, Taibah University, P.O. Box 84901, Riyadh 11681, Saudi Arabia.
Yahia N MabkhotDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, P.O. Box 960, Abha 61421, Saudi Arabia.
JSS Academy of Higher Education and Research · INKing Khalid University · SAKing Saud University · SATaibah University · SA

Funding

JSS Academy of Higher Education and Research Reg/ACA/ M Pharm C&P/347/2016-17
6 · The paper itself

Abstract

The current study was intended to fabricate and evaluate ultrasonically assisted quercetin nanoemulsion (Que-NE) for improved bioavailability and therapeutic effectiveness against diabetes mellitus in rats. Ethyl oleate, Tween 20, and Labrasol were chosen as oil, surfactant, and cosurfactant, respectively. Box-Behnken design (BBD) was employed to study the influence of process variables such as % surfactant and cosurfactant mixture (Smix) (5 to 7%), % amplitude (20-30%) and sonication time (2.5-7.5 min) on droplet size, polydispersibility index (PDI), and % entrapment efficiency (%EE) were studied. The optimization predicted that 9% Smix at 25% amplitude for 2.5 min would produce Que-NE with a droplet size of 125.51 nm, 0.215 PDI, and 87.04% EE. Moreover, the optimized Que-NE exhibited appreciable droplet size and PDI when stored at 5, 30, and 40 °C for 45 days. Also, the morphological characterization by transmission electron microscope (TEM) indicated the spherical shape of the optimized nanoemulsion. Furthermore, the Que-NE compared to pure quercetin exhibited superior release and enhanced oral bioavailability. The streptozocin-induced antidiabetic study in rats revealed that the Que-NE had remarkable protective and therapeutic properties in managing body weight, blood glucose level, lipid profile, and tissue injury markers, alongside the structure of pancreatic β-cells and hepatocytes being protected. Thus, the developed Que-NE could be of potential use as a substitute strategy for diabetes.

Indexed as

Box–Behnken designdiabetes mellitusnanoemulsionoptimizationquercetinultrasonication

Identifiers

PMID35056127
PMCPMC8779357
OpenAlexW4206035393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.